-
GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development
•
Suzhou based biotech firm GeneQuantum has announced a series of major commercial cooperation pacts worth USD 13 billion with US – based Biohaven Pharmaceutical (NYSE: BHVN) and South Korean biotech Aimed Bio Inc. The agreements coincide with the global launch of GeneQuantum’s IDiscovery, an intelligent automated development system for bioconjugated…
